| Placebo N = 128 | TXA N = 130 |
---|---|---|
Bleeding controlled with treatment only –(no additional intervention)a | 77 (60.2) | 74 (56.9) |
Bleeding controlled with treatment only –(no additional serious intervention)b | 102 (79.7) | 108 (83.1) |
Additional interventions | ||
 Oxytocin | 37 (28.9) | 39 (30.0) |
  IV | 25 (19.5) | 25 (19.2) |
  IM | 12 (9.4) | 14 (10.8) |
Ergometrine | 34 (26.6) | 34 (26.2) |
Syntocinon | 1 (0.8) | 1 (0.8) |
Carbetocin IV | 10 (7.8) | 14 (10.8) |
Misoprostol | 0 (0.) | 1 (0.8) |
TXA IV | 16 (12.5) | 17 (13.1) |
Uterine evacuation (MVA) | 0 (0.0) | 1 (0.8) |
Bimanual compression | 8 (6.3) | 8 (6.2) |
Suturing | 111 (86.7) | 108 (83.1) |
Uterine packing | 15 (11.7) | 10 (7.7) |
Blood transfusion | 13 (10.2) | 12 (9.2) |
Uterine artery ligature | 1 (0.8) | 0 (0) |
Hysterectomy | 1 (0.8) | 0 (0) |
Tissue repair | 2 (1.6) | 1 (0.8) |
Plasma expanders | 4 (3.1) | 3 (2.3) |